December 9, 2019

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

Paris, France, December 9, 2019, 7.30 am CET – The National Eye Hospital (CHNO) of the Quinze-Vingts in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR001318...
Read more
December 9, 2019

BONESUPPORTTM CERTiFy STUDY ON CERAMENT® BONE VOID FILLER NOW PUBLISHED IN THE JOURNAL OF BONE AND JOINT SURGERY

Lund, Sweden, 08:45 CET, December 9 2019 BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone injuries, today announced the publication of the Level I cli...
Read more
December 8, 2019

Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019

STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at...
Read more
December 6, 2019

Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting

Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10th, 2019, at 13:00 (CET...
Read more
December 4, 2019

Nordic Nanovector: New preclinical data offer insights into enhancing Betalutin®-based therapies in NHL

Oslo, Norway, 4 December 2019 Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical studies investigating the effect of Betalutin® (177Lu-lilotomab s...
Read more
December 2, 2019

Oncopeptides appoints Joseph Horvat as President North America

Stockholm – December 2, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopeti...
Read more
December 2, 2019

Orexo appoints Dennis Urbaniak as Executive Vice President Digital Health

Appointment strengthens Orexo’s competencies and resources within digital health Orexo committed to finding innovative solutions to improve treatment of addiction Uppsa...
Read more
November 27, 2019

Orexo acquires exclusive US rights to commercialize vorvida®, a digital therapy for alcohol use disorder with scientifically proven efficacy

-Deal further strengthens Orexo’s partnership with GAIA -Orexo committed to digital health to address addiction Uppsala, Sweden – November 27, 2019. Orexo AB (pub...
Read more
November 19, 2019

Interim Report Q3 2019

November 19, 2019 - Regulatory press release Press releases Summary Financial overview July 1 – September 30, 2019 Net sales amounted to SEK 0.0 M (0.0) Los...
Read more
November 19, 2019

Nordic Nanovector ASA – Results for the Third Quarter 2019

Oslo, Norway, 19 November 2019 Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2019. A presentation by the company's senior management te...
Read more